New cell therapy aims to fight hard-to-treat blood cancers
NCT ID NCT07574346
First seen May 08, 2026 · Last updated May 24, 2026 · Updated 2 times
Summary
This early-stage study tests a new treatment called IASO207 for people with B-cell blood cancers that have come back or not responded to other treatments. The main goals are to check safety and find the right dose. About 18 adults aged 18 to 75 will take part. The treatment uses specially modified cells to attack cancer cells, but it is not expected to be a cure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANCIES are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.